Publications

Selected publications

For full list of publications : ORCID: 0000-0002-4871-8818

• Developmental trajectory of the healthy human gut microbiota during the first 5 years of life. 
  Roswall, J., Olsson, L.M., Kovatcheva-Datchary, P., Nilsson, S., Tremaroli, V., Simon, M.C., Kiilerich, P., Akrami, R., Krämer, M., Uhlén, M., Gummesson, A., Kristiansen, K., Dahlgren, J., Bäckhed, F. Cell Host Microbe (2021)
  Describing the establishment of the gut microbiota during the first five years of life.
• Microbial Imidazole Propionate Affects Responses to Metformin through p38γ-Dependent Inhibitory AMPK Phosphorylation 
  Koh, A., Mannerås-Holm, L., Yunn, Na Oh, Nilsson, Peter M., Ryu, SH., Molinaro, A., Perkins, R., Smith, G., Bäckhed, F. Cell Metabolism (2020)
  Showing that imidazole propionate impairs the glucose-lowering effect of the antidiabetic drug metformin and inhibits metformin-induced AMPK activation by activating p38γ/Akt/inhibitory AMPK serine phosphorylation.
• Gut microbial metabolites as multi-kingdom intermediates
  Krautkramer KA, Fan J, Bäckhed F. Nature Reviews Microbiology (2020)
  Review discussing the role of microbial produced metabolites on host metabolism.
• The gut microbiota in prediabetes and diabetes: a population-based cross-sectional study
  Wu, H., Tremaroli, V., Schmidt, C., Lundqvist, A., Olsson, L.M., Krämer, M., Gummesson, A., Perkins, R.,Bergström, G., Bäckhed, F. Cell Metabolism (2020)
  Largest study on diabetes and microbiome to date demonstrating that the microbiota is altered in pre-diabetes and type 2 diabetes independent of medication.
• Microbe-produced imidazole propionate impairs insulin signaling via p38γ/p62/mTORC1
  Koh, A., Molinaro, A., Ståhlman, M., Khan, M.T., Schmidt, C., Mannerås-Holm, L., Wu, H., Carreras, A., Jeong, H., Olofsson, L., Bergh, P., Gerdes, V., Hartstra, A, de Brauw, D., Perkins, R., Nieuwdorp, M., Bergström, G.,Bäckhed, F. Cell (2018)
  Identified imidazole propionate to be microbially produced and elevated in subjects with type 2 diabetes. In mice, we demonstrated that injection of the metabolite caused insulin resistance. We also identified the signaling pathway leading to cellular insulin resistance.

• Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug 
  Wu, H., Esteve, E., Tremaroli, V., Khan, M.T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L.M., Serino, M., Planas-Fèlix, M., Xifra, G., Mercader, J.M., Torrents, D., Burcelin, R., Ricart, W., Perkins, R., Fernàndez-Real, J.M., Bäckhed, F. Nature Medicine (2017)
  Demonstrated that the antidiabetic drug metformin alters the microbiome and that this alteration contributes to improved glucose metabolism.
• Dietary fiber improvement of glucose metabolism is associated with abundance of Prevotella
  Kovatcheva-Datchary, P., Nilsson, A., Akrami, R., Lee, Y.S., De Vadder, F., Arora, T., Hallen, A., Martens, E., Björck, I., Bäckhed, F. Cell Metabolism (2015)
  Identified that fibers in barley-kernels mediate their metabolic beneficial effects through interactions with Prevotella.
• Gut metagenome in European women with normal, impaired and diabetic glucose control  
  Karlsson, F., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., Bäckhed, F. Nature (2013)
  Identified a diabetes associated microbiota and developed a model to classify patients from controls.
• The gut microbiota as an environmental factor that regulates fat storage 
  Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, CF., Gordon, J. I. Proceeding of National Academy of Sciences USA, PNAS (2004)
  First paper to demonstrate that the gut microbiota contributes to adiposity.